STAT3 inhibitors as a tool for eliminating negative effects of chemotherapy

STAT3 is a conveniently challenging therapeutic approach to cancer treatment. It can be assumed that the inhibition of the STAT3 pathway is a powerful tool for the elimination of the detrimental effects of chemotherapy and/or for increasing its effectiveness. The STAT3 pathway inhibition is also expected to increase the efficacy of anti-tumour immunotherapy. The objective of this collaborative project is to synthesize new potentially druggable STAT3 inhibitors, to evaluate their inhibitory capabilities, their toxicity, and their impacts on (senescent) tumour cells treated with selected chemotherapeutics when comparing them with the existing STAT3 inhibitors. On the basis of the experimental chemo- and/or immune-therapeutic proof of the principle experiments performed and using preclinical murine tumour models, we will propose a therapeutic scheme in which STAT3 inhibitors would eliminate the adverse effects of the genotoxic anti-tumour therapy, as well as the detrimental effects of senescent cells. The main intention is to prevent development of a residual tumour disease and to increase the effectiveness of the subsequent immunotherapy.

Researcher:
RNDr. Milan Reiniš, CSc.
E-mail milan.reinis@img.cas.cz
Institution: Institute of Molecular Genetics of the Czech Academy of Sciences